These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 18067998)

  • 1. CT-based texture analysis potentially provides prognostic information complementary to interim fdg-pet for patients with hodgkin's and aggressive non-hodgkin's lymphomas.
    Ganeshan B; Miles KA; Babikir S; Shortman R; Afaq A; Ardeshna KM; Groves AM; Kayani I
    Eur Radiol; 2017 Mar; 27(3):1012-1020. PubMed ID: 27380902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET/CT: Clinical role in lymphomas.
    Papathanasiou N
    Hell J Nucl Med; 2023; 26 Suppl():36-37. PubMed ID: 37658560
    [No Abstract]   [Full Text] [Related]  

  • 3. Ultra-early response assessment in lymphoma treatment: [
    Mayerhoefer ME; Raderer M; Jaeger U; Staber P; Kiesewetter B; Senn D; Gallagher FA; Brindle K; Porpaczy E; Weber M; Berzaczy D; Simonitsch-Klupp I; Sillaber C; Skrabs C; Haug A
    Eur J Nucl Med Mol Imaging; 2018 Jun; 45(6):931-940. PubMed ID: 29480328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage disease.
    Evens AM; Kostakoglu L
    Blood; 2014 Nov; 124(23):3356-64. PubMed ID: 25428223
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on FDG-PET in pediatric lymphoma.
    Kurch L; Kluge R
    Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):58-69. PubMed ID: 38587361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.
    Barrington SF; Kluge R
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(Suppl 1):97-110. PubMed ID: 28411336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDG-PET imaging in hematological malignancies.
    Valls L; Badve C; Avril S; Herrmann K; Faulhaber P; O'Donnell J; Avril N
    Blood Rev; 2016 Jul; 30(4):317-31. PubMed ID: 27090170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evolving role of F-FDG PET scans in patients with aggressive non-Hodgkin's lymphoma.
    Hosein PJ; Lossos IS
    European J Clin Med Oncol; 2010 Feb; 2(1):131-138. PubMed ID: 22140415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnostic Accuracy of
    Naveed S; Faheem H; Shazlee K; Ashraf MS
    Pak J Med Sci; 2023; 39(6):1830-1834. PubMed ID: 37936727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
    Younes A; Hilden P; Coiffier B; Hagenbeek A; Salles G; Wilson W; Seymour JF; Kelly K; Gribben J; Pfreunschuh M; Morschhauser F; Schoder H; Zelenetz AD; Rademaker J; Advani R; Valente N; Fortpied C; Witzig TE; Sehn LH; Engert A; Fisher RI; Zinzani PL; Federico M; Hutchings M; Bollard C; Trneny M; Elsayed YA; Tobinai K; Abramson JS; Fowler N; Goy A; Smith M; Ansell S; Kuruvilla J; Dreyling M; Thieblemont C; Little RF; Aurer I; Van Oers MHJ; Takeshita K; Gopal A; Rule S; de Vos S; Kloos I; Kaminski MS; Meignan M; Schwartz LH; Leonard JP; Schuster SJ; Seshan VE
    Ann Oncol; 2017 Jul; 28(7):1436-1447. PubMed ID: 28379322
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Chemotherapy on Aortic 18-Fluorodeoxyglucose Uptake in┬áPatients With Hodgkin and Non-Hodgkin Lymphoma.
    Vlachopoulos CV; Solomou EG; Terentes Printzios DG; Pouli AG; Sioni A; Giannouli SE; Angelopoulou MK; Kafouris P; Metaxas MG; Chondropoulos SD; Stergiou IE; Marinakis TP; Koutagiar I; Miliou AA; Ioakeimidis N; Tsalamandris ST; Katsi V; Aggeli CI; Voulgarelis M; Tousoulis DM; Tsioufis C; Anagnostopoulos CD
    JACC Adv; 2023 Mar; 2(2):100277. PubMed ID: 38938303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
    Hoppe RT; Advani RH; Ai WZ; Ambinder RF; Armand P; Bello CM; Benitez CM; Bierman PJ; Boughan KM; Dabaja B; Gordon LI; Hernandez-Ilizaliturri FJ; Herrera AF; Hochberg EP; Huang J; Johnston PB; Kaminski MS; Kenkre VP; Khan N; Lynch RC; Maddocks K; McConathy J; McKinney M; Metzger M; Morgan D; Mulroney C; Rabinovitch R; Rosenspire KC; Seropian S; Tao R; Winter JN; Yahalom J; Burns JL; Ogba N
    J Natl Compr Canc Netw; 2020 Jun; 18(6):755-781. PubMed ID: 32502987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD012643. PubMed ID: 31930780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
    Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of mediastinal lymph nodes using F-FDG PET-CT scan and its histopathologic correlation.
    Kumar A; Dutta R; Kannan U; Kumar R; Khilnani GC; Gupta SD
    Ann Thorac Med; 2011 Jan; 6(1):11-6. PubMed ID: 21264165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET.
    Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G
    Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
    Kostakoglu L; Coleman M; Leonard JP; Kuji I; Zoe H; Goldsmith SJ
    J Nucl Med; 2002 Aug; 43(8):1018-27. PubMed ID: 12163626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma.
    Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E
    Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic value of 18F-FDG PET-CT in the management of Hodgkin's lymphoma: preliminary results of a prospective study.
    Paolini R; Rampin L; Rodella E; Ramazzina E; Banti E; Al-Nahhas A; Rubello D
    Nucl Med Rev Cent East Eur; 2007; 10(2):87-90. PubMed ID: 18228212
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.